| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SGCG |
| Uniprot No | Q13326 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-291 aa |
| 活性数据 | MVREQYTTATEGICIERPENQYVYKIGIYGWRKRCLYLFVLLLLIILVVNLALTIWILKVMWFSPAGMGHLCVTKDGLRLEGESEFLFPLYAKEIHSRVDSSLLLQSTQNVTVNARNSEGEVTGRLKVGPKMVEVQNQQFQINSNDGKPLFTVDEKEVVVGTDKLRVTGPEGALFEHSVETPLVRADPFQDLRLESPTRSLSMDAPRGVHIQAHAGKIEALSQMDILFHSSDGMLVLDAETVCLPKLVQGTWGPSGSSQSLYEICVCPDGKLYLSVAGVSTTCQEHSHICL |
| 分子量 | 58.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SGCG(γ-肌聚糖)蛋白的模拟参考文献示例(实际文献需通过学术数据库查询)：
---
1. **"Expression and purification of recombinant human γ-sarcoglycan for muscular dystrophy studies"**
- **作者**: Thompson, J.R. et al.
- **摘要**: 该研究通过大肠杆菌表达系统成功克隆并纯化了重组人SGCG蛋白，验证其与肌细胞膜复合物的结合能力，为研究SGCG缺失型肢带型肌营养不良症(LGMD2C)的分子机制提供工具。
2. **"Functional analysis of γ-sarcoglycan mutations in vitro"**
- **作者**: Li, X. & Wang, H.
- **摘要**: 通过体外细胞模型研究SGCG蛋白的突变对其与肌营养不良蛋白复合体相互作用的影响，发现特定错义突变导致蛋白质错误折叠，影响肌细胞膜的稳定性。
3. **"Adeno-associated virus-mediated SGCG gene therapy in a mouse model of LGMD2C"**
- **作者**: Morales, S. et al.
- **摘要**: 在小鼠模型中，通过AAV载体递送重组SGCG基因，显著恢复肌纤维膜的完整性并改善肌肉功能，支持基因治疗在LGMD2C中的潜力。
4. **"Structural insights into γ-sarcoglycan by cryo-EM"**
- **作者**: Zhang, Y. et al.
- **摘要**: 利用冷冻电镜解析重组人SGCG蛋白的三维结构，揭示其与其他肌聚糖家族成员结合的界面特征，为设计靶向药物提供结构基础。
---
**备注**：以上文献名称和作者为虚构示例，实际研究需参考PubMed、Web of Science等数据库的真实文献(如搜索关键词：SGCG, gamma-sarcoglycan, LGMD2C)。
**Background of Recombinant Human SGCG Protein**
Sarcoglycan gamma (SGCG), encoded by the *SGCG* gene, is a critical component of the dystrophin-glycoprotein complex (DGC) in muscle cell membranes. This complex stabilizes sarcolemma during contraction and links the cytoskeleton to the extracellular matrix, ensuring mechanical resilience. Mutations in *SGCG* cause limb-girdle muscular dystrophy type 2C (LGMD2C), characterized by progressive muscle weakness and degeneration.
Recombinant human SGCG protein is engineered via heterologous expression systems (e.g., mammalian cells or bacteria) to produce functional, purified SGCG for research and therapeutic exploration. Its production enables studies on DGC assembly, disease mechanisms, and potential treatments. Researchers use recombinant SGCG to investigate protein-protein interactions, screen drugs targeting sarcolemmal stability, and develop gene therapies or enzyme replacement strategies for LGMD2C.
Despite advances, challenges remain in achieving proper post-translational modifications and membrane integration in vitro. Ongoing studies focus on optimizing recombinant SGCG’s structural fidelity and therapeutic efficacy, highlighting its dual role as a molecular tool and a candidate for addressing sarcoglycanopathies.
×
